These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 20656084)

  • 21. Skeletal remodeling following clinically relevant radiation-induced bone damage treated with zoledronic acid.
    Hui SK; Fairchild GR; Kidder LS; Sharma M; Bhattacharya M; Jackson S; Le C; Yee D
    Calcif Tissue Int; 2012 Jan; 90(1):40-9. PubMed ID: 22083107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Uniform partial dissolution of bone mineral by using fluoride and phosphate ions combination.
    DePaula CA; Pan Y; Guzelsu N
    Connect Tissue Res; 2008; 49(5):328-42. PubMed ID: 18991086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat.
    Gasser JA; Ingold P; Venturiere A; Shen V; Green JR
    J Bone Miner Res; 2008 Apr; 23(4):544-51. PubMed ID: 18072878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cortical bone composition and orientation as a function of animal and tissue age in mice by Raman spectroscopy.
    Gamsjaeger S; Masic A; Roschger P; Kazanci M; Dunlop JW; Klaushofer K; Paschalis EP; Fratzl P
    Bone; 2010 Aug; 47(2):392-9. PubMed ID: 20450992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
    Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
    Croucher PI; De Hendrik R; Perry MJ; Hijzen A; Shipman CM; Lippitt J; Green J; Van Marck E; Van Camp B; Vanderkerken K
    J Bone Miner Res; 2003 Mar; 18(3):482-92. PubMed ID: 12619933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading.
    Feher A; Koivunemi A; Koivunemi M; Fuchs RK; Burr DB; Phipps RJ; Reinwald S; Allen MR
    Bone; 2010 Jan; 46(1):203-7. PubMed ID: 19857619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short-term zoledronic acid reduces trabecular bone remodeling in dogs.
    Helm NB; Padala S; Beck FM; D'Atri AM; Huja SS
    Eur J Oral Sci; 2010 Oct; 118(5):460-5. PubMed ID: 20831579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone-related growth factors and zoledronic acid regulate the PTHrP/PTH.1 receptor bioregulation systems in MG-63 human osteosarcoma cells.
    Tenta R; Sourla A; Lembessis P; Koutsilieris M
    Anticancer Res; 2006; 26(1A):283-91. PubMed ID: 16475708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of zoledronic acid on sutural bone formation: a computed tomography study.
    Oztürk F; Babacan H; Gümüs C
    Eur J Orthod; 2012 Apr; 34(2):141-6. PubMed ID: 21382907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.
    Tanaka M; Mori H; Kayasuga R; Ochi Y; Kawada N; Yamada H; Kishikawa K
    Bone; 2008 Nov; 43(5):894-900. PubMed ID: 18687415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Degradable bisphosphonate-alkaline phosphatase-complexed hydroxyapatite implants in vitro.
    Denissen H; van Beek E; van den Bos T; de Blieck J; Klein C; van den Hooff A
    J Bone Miner Res; 1997 Feb; 12(2):290-7. PubMed ID: 9041063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Doses effects of zoledronic acid on mineral apatite and collagen quality of newly-formed bone in the rat's calvaria defect.
    Olejnik C; Falgayrac G; During A; Cortet B; Penel G
    Bone; 2016 Aug; 89():32-39. PubMed ID: 27168397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bisphosphonate protonation states, conformations, and dynamics on bone mineral probed by solid-state NMR without isotope enrichment.
    Ironside MS; Duer MJ; Reid DG; Byard S
    Eur J Pharm Biopharm; 2010 Sep; 76(1):120-6. PubMed ID: 20554022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone chemical structure response to mechanical stress studied by high pressure Raman spectroscopy.
    de Carmejane O; Morris MD; Davis MK; Stixrude L; Tecklenburg M; Rajachar RM; Kohan DH
    Calcif Tissue Int; 2005 Mar; 76(3):207-13. PubMed ID: 15742234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
    Reid IR; Brown JP; Burckhardt P; Horowitz Z; Richardson P; Trechsel U; Widmer A; Devogelaer JP; Kaufman JM; Jaeger P; Body JJ; Brandi ML; Broell J; Di Micco R; Genazzani AR; Felsenberg D; Happ J; Hooper MJ; Ittner J; Leb G; Mallmin H; Murray T; Ortolani S; Rubinacci A; Saaf M; Samsioe G; Verbruggen L; Meunier PJ
    N Engl J Med; 2002 Feb; 346(9):653-61. PubMed ID: 11870242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo bone augmentation in an osteoporotic environment using bisphosphonate-loaded calcium deficient apatite.
    Verron E; Gauthier O; Janvier P; Pilet P; Lesoeur J; Bujoli B; Guicheux J; Bouler JM
    Biomaterials; 2010 Oct; 31(30):7776-84. PubMed ID: 20643480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemical makeup of microdamaged bone differs from undamaged bone.
    Ruppel ME; Burr DB; Miller LM
    Bone; 2006 Aug; 39(2):318-24. PubMed ID: 16584933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complementary information on in vitro conversion of amorphous (precursor) calcium phosphate to hydroxyapatite from Raman microspectroscopy and wide-angle X-ray scattering.
    Kazanci M; Fratzl P; Klaushofer K; Paschalis EP
    Calcif Tissue Int; 2006 Nov; 79(5):354-9. PubMed ID: 17120187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.